Target: ₹2,305
CMP: ₹1,932.80
Pune headquartered Emcure Pharmaceuticals is a diversified pharma player focused on developing, manufacturing and marketing a broad range of pharmaceutical products in the domestic/international markets.
Emcure’s domestic business combines a strong position in chronic and acute therapies, leadership in Women ’s care, a sizeable Injectables franchise and a differentiated front-end platform through Zuventus. Importantly, the company has multiple relatively low-risk growth opportunities through strategic in-licensing partnerships with global innovators, providing access to established products and emerging therapy areas without incurring significant R&D investments. The GLP -1 opportunity, expansion into MASH, Ophthalmics, Dermatology and Consumer Health provide additional optionality beyond the core portfolio.
Internationally, Emcure has built strong front-end capabilities through a well-executed acquisition-led strategy in Canada and Europe, while maintaining a vertically integrated supply chain through its Indian manufacturing base. Its large and diversified product pipeline, presence in complex generics and differentiated opportunities such as Semaglutide, Liposomal Amphotericin B and Lenacapavir strengthen medium-term growth visibility.
The combination of a diversified domestic franchise, scalable international platforms, proven M&A execution and multiple complex -product opportunities offer a stronger and more diversified growth profile.
We value Emcure Pharma at ₹2,305 per share, based on 30x FY28E EPS of ₹76.8.